Compare SQNS & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | BDSX |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Semiconductors | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 88.3M |
| IPO Year | N/A | N/A |
| Metric | SQNS | BDSX |
|---|---|---|
| Price | $3.06 | $12.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $20.33 | ★ $32.50 |
| AVG Volume (30 Days) | 260.1K | ★ 262.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $22.01 |
| Revenue Next Year | $70.61 | $26.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.97 | $3.44 |
| 52 Week High | $58.30 | $20.40 |
| Indicator | SQNS | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 30.36 | 67.15 |
| Support Level | $3.01 | $9.83 |
| Resistance Level | $3.81 | $13.63 |
| Average True Range (ATR) | 0.39 | 1.37 |
| MACD | -0.10 | 0.08 |
| Stochastic Oscillator | 4.39 | 79.75 |
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.